Asset
Ulacamten
Cytokinetics Incorporated Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05877053 | phase1 | completed | 2023-05-09 | 2024-11-20 | Cytokinetics | A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants |
| NCT06793371 | phase2 | recruiting | 2025-02-06 | 2026-09-01 | Cytokinetics | AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF |
FDA applications (0)
This company has no applications containing this asset.